Citation: Yonghui Qiao, Zhihao Wei, Tingting Qin, Rufeng Song, Zhiqiang Yu, Qi Yuan, Juan Du, Qingbing Zeng, Lanlan Zong, Shaofeng Duan, Xiaohui Pu. Combined nanosuspensions from two natural active ingredients for cancer therapy with reduced side effects[J]. Chinese Chemical Letters, ;2021, 32(9): 2877-2881. doi: 10.1016/j.cclet.2021.03.049 shu

Combined nanosuspensions from two natural active ingredients for cancer therapy with reduced side effects

Yonghui Qiao ^a ,
Zhihao Wei ^b ,
Tingting Qin ^c ,
Rufeng Song ^b ,
Zhiqiang Yu ^c ,
Qi Yuan ^b ,
Juan Du ^d ,
Qingbing Zeng ^c,, ,
Lanlan Zong ^b,, ,
Shaofeng Duan ^b,, ,
Xiaohui Pu ^b,,

a.
Henan University of Chinese Medicine, Zhengzhou 450046, China
b.
Institute of Pharmacy, School of Pharmacy, Henan University, Kaifeng 475004, China
c.
School of Pharmaceutics Sciences, Southern Medical University, Guangzhou 510515, China
d.
Department of Pharmacy, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450003, China

Corresponding author: Qingbing Zeng, zengqb@smu.edu.cn Lanlan Zong, lanlan19890321@126.com Shaofeng Duan, dsf_2007@163.com Xiaohui Pu, pgh425@163.com
Received Date: 12 January 2021
Revised Date: 17 March 2021
Accepted Date: 19 March 2021
Available Online: 22 March 2021

Figures(5)

Tumor drug resistance and systemic side effects of chemotherapeutic drugs are the main reasons for the failure of cancer treatment. In recent years, it was found that some natural active ingredients can reverse MDR and regulate body immunity to enhance the efficacy and reduce toxicity of chemotherapeutic drugs. In this paper, a new nanosuspensions, HCPT and QUR hybrid nanosuspensions (HQ-NPs), was prepared by the microprecipitation-high pressure homogenization method to reverse tumor drug resistance, reduce toxicity, and increase therapeutic efficacy. The in vitro investigation results showed that HQ-NPs had a unique shape (particle size was about 216.3±5.9 nm), changed crystalline, and different dissolution rates compared with HCPT-NPs and QUR-NPs, which is attributed to the strong intermolecular forces between HCPT and QUR as indicated by the results of the molecule dock. It was verified that the HQ-NPs could double the retention of HCPT in cells and enhance the cytotoxicity to A549/PTX cells in vitro tests compared with HCPT-NPs. We also found that HQ-NPs can significantly enhance the accumulation of HCPT in tumor sites, improve the antitumor activity of HCPT, and protect the immune organs and other normal tissues (P < 0.01), compared with HCPT-NPs. Therefore, hybrid nanosuspensions can offer promising potential as the drug delivery system for HCPT and QUR to increase the therapeutic efficacy and reduce the toxicity of HCPT.
- Combination therapy,
- Multidrug resistance,
- Nanosuspensions,
- Antitumor activity,
- Immunomodulatory
1. [1]
  E. Dubikovskaya, S. Thorne, T. Pillow, C. Contag, P. Wender, Proc. Natl. Acad. Sci. U. S. A. 105(2008) 12128-12133. doi: 10.1073/pnas.0805374105
2. [2]
  C.X. Yang, L. Xing, X. Chang, et al., Mol. Pharm. 17(2020) 1300-1309. doi: 10.1021/acs.molpharmaceut.9b01318
3. [3]
  M.R. Salehan, H.R. Morse, Br. J. Biomed. Sci. 70(2013) 31-40. doi: 10.1080/09674845.2013.11669927
4. [4]
  Y. Sun, W. Ma, Y. Yang, et al., Asian J. Pharm. Sci. 14(2019) 581-594. doi: 10.1016/j.ajps.2019.04.005
5. [5]
  Y. Zhang, F. Wang, M. Li, et al., Adv. Sci. 5(2018) 1800811. doi: 10.1002/advs.201800811
6. [6]
  L. Sun, D. Wang, Y. Chen, et al., Biomaterials 133(2017) 219-228. doi: 10.1016/j.biomaterials.2017.04.028
7. [7]
  T.J. Curiel, Drug Resist. Updat. 15(2012) 106-113. doi: 10.1016/j.drup.2012.03.003
8. [8]
  Y. Liu, Y.J. Kim, N. Siriwon, et al., Biotechnol. Bioeng. 115(2018) 1403-1415. doi: 10.1002/bit.26566
9. [9]
  W. Zhang, J. Shen, H. Su, et al., ACS Appl. Mater. Interfaces 8(2016) 13332-13340. doi: 10.1021/acsami.6b03881
10. [10]
  Q. Huo, J. Zhu, Y. Niu, et al., Int. J. Nanomedicine 12(2017) 8631-8647. doi: 10.2147/IJN.S144452
11. [11]
  J. Wang, F. Wang, F. Li, et al., J. Mater. Chem. B Mater. Biol. Med. 4(2016) 2954-2962. doi: 10.1039/C5TB02450A
12. [12]
  H. Wang, L. Zhou, K. Xie, et al., Theranostics 8(2018) 3949-3963. doi: 10.7150/thno.26161
13. [13]
  W. Han, L. Shi, B. Xie, et al., ACS Appl. Mater. Interfaces 12(2020) 1707-1720. doi: 10.1021/acsami.9b20178
14. [14]
  X.H. Pu, J. Sun, Y.M. Qin, et al., Curr. Nanosci. 8(2012) 762-766. doi: 10.2174/157341312802884553
15. [15]
  L. Yang, J. Hong, J. Di, et al., Int. J. Nanomedicine 12(2017) 3681-3695. doi: 10.2147/IJN.S134005
16. [16]
  X.H. Pu, J. Sun, J.H. Han, et al., J. Nanopart. Res. 15(2013) 2043-2055. doi: 10.1007/s11051-013-2043-1
17. [17]
  Y. Qiao, Y. Cao, K. Yu, L. Zong, X. Pu, Int. J. Pharm. 589(2020) 119830. doi: 10.1016/j.ijpharm.2020.119830
18. [18]
  H.B. Hyun, J.Y. Moon, S.K. Cho, Molecules 23(2018) 209. doi: 10.3390/molecules23020209
19. [19]
  Z. Zhang, S. Xu, Y. Wang, et al., J. Colloid Interface Sci. 509(2018) 47-57. doi: 10.1016/j.jcis.2017.08.097
20. [20]
  A. Primikyri, M.V. Chatziathanasiadou, E. Karali, et al., ACS Chem. Biol. 9(2014) 2737. doi: 10.1021/cb500259e
21. [21]
  B. Cote, L.J. Carlson, D.A. Rao, A.W.G. Alani, J. Control. Release 213(2015) 128-133. doi: 10.1016/j.jconrel.2015.06.040
22. [22]
  X. Wang, Y. Chen, F.Z. Dahmani, et al., Biomaterials 35(2014) 7654-7665. doi: 10.1016/j.biomaterials.2014.05.053
23. [23]
  M. Li, Y. Chen, L. Yin, et al., Sci. Adv. Mater. 9(2017) 1713-1723. doi: 10.1166/sam.2017.3229
24. [24]
  X.H. Pu, J. Sun, M. Li, Z.G. He, Curr. Nanosci. 5(2009) 417-427. doi: 10.2174/157341309789378177
25. [25]
  J. Li, Q. Fu, X. Liu, M. Li, Y. Wang, Arch. Pharm. Res. 39(2016) 202-212. doi: 10.1007/s12272-015-0685-5
26. [26]
  H. Yang, F. Teng, P. Wang, et al., Int. J. Pharm. 477(2014) 88-95. doi: 10.1016/j.ijpharm.2014.10.025
27. [27]
  D. An, J. Fu, Z. Xie, et al., J. Mater. Chem. B:Mater. Biol. Med. 8(2020) 7076-7120. doi: 10.1039/D0TB00824A
28. [28]
  Q. Liu, Z. Xie, M. Qiu, et al., Adv. Sci. 7(2020) 2001191. doi: 10.1002/advs.202001191
29. [29]
  M. Qiu, D. Zhu, L. Yan, et al., J. Phys. Chem. C 120(2016) 22757-22765. doi: 10.1021/acs.jpcc.6b03756
30. [30]
  M. Qiu, R.G. Brandt, Y. Niu, et al., J. Phys. Chem. C 119(2015) 8501-8511.
31. [31]
  Q. Peng, J. Liu, T. Zhang, et al., Biomacromolecules 20(2019) 1789-1797. doi: 10.1021/acs.biomac.9b00175
32. [32]
  Y. Lu, Y. Lv, T. Li, Adv. Drug Deliv. Rev. 143(2019) 115-133. doi: 10.1016/j.addr.2019.06.006
33. [33]
  X. Tian, L. Zhang, M. Yang, et al., WIREs Nanomed. Nanobiotech. 10(2018) e1476.
34. [34]
  L. Zong, X. Li, H. Wang, et al., Int. J. Pharm. 531(2017) 108-117. doi: 10.1016/j.ijpharm.2017.08.082
35. [35]
  Y. Kojo, S. Matsunaga, H. Suzuki, et al., Eur. J. Pharm. Sci. 97(2017) 55-61. doi: 10.1016/j.ejps.2016.10.032
36. [36]
  X. Zhang, T. Zhang, Y. Lan, B. Wu, Z. Shi, AAPS PharmSciTech 17(2016) 400-408. doi: 10.1208/s12249-015-0363-4
37. [37]
  G.Y. Zhu, B.Y. Lu, T.X. Zhang, et al., Nanomed. 13(2018) 1093-1106. doi: 10.2217/nnm-2017-0391
38. [38]
  B.Y. Lu, G.Y. Zhu, C.H. Yu, et al., Nano Res. 14(2020) 185-190.
39. [39]
  Q. Yuan, Y. Wang, R. Song, et al., Front. Pharmacol. 10(2019) 225. doi: 10.3389/fphar.2019.00225
40. [40]
  H. Gao, Q. He, Expert Opin. Drug Deliv. 11(2014) 409-420. doi: 10.1517/17425247.2014.877442
41. [41]
  X. Pu, L. Zhao, J. Li, et al., Acta Biomater. 88(2019) 357-369. doi: 10.1016/j.actbio.2019.02.039
42. [42]
  L. Mei, Y. Liu, H. Zhang, et al., ACS Appl. Mater. Interfaces 8(2016) 9577-9589. doi: 10.1021/acsami.5b12347
43. [43]
  H.B. Ruttala, T. Ramasamy, B.S. Shin, et al., Int. J. Pharm. 519(2017) 11-21. doi: 10.1016/j.ijpharm.2017.01.011
44. [44]
  Y. Cao, Z. Wei, M. Li, et al., Curr. Cancer Drug Targets 19(2019) 338-347. doi: 10.2174/1568009618666180629150927
45. [45]
  D.R. Reddy, A. Khurana, S. Bale, et al., Springerplus 5(2016) 1618. doi: 10.1186/s40064-016-3267-1
46. [46]
  M. Han, X. Liu, Y. Guo, Y. Wang, X. Wang, Int. J. Pharm. 455(2013) 85-92. doi: 10.1016/j.ijpharm.2013.07.056
47. [47]
  L. Yang, J. Jiang, J. Hong, et al., J. Biomed. Nanotechnol. 11(2015) 711-721. doi: 10.1166/jbn.2015.2050
1. [1]
  Ningyue Xu , Jun Wang , Lei Liu , Changyang Gong . Injectable hydrogel-based drug delivery systems for enhancing the efficacy of radiation therapy: A review of recent advances. Chinese Chemical Letters, 2024, 35(8): 109225-. doi: 10.1016/j.cclet.2023.109225
2. [2]
  Tingting Hu , Chao Shen , Xueyan Wang , Fengbo Wu , Zhiyao He . Tumor microenvironment-sensitive polymeric nanoparticles for synergetic chemo-photo therapy. Chinese Chemical Letters, 2024, 35(11): 109562-. doi: 10.1016/j.cclet.2024.109562
3. [3]
  Hao Sun , Shengke Li , Qian Liu , Minzan Zuo , Xueqi Tian , Kaiya Wang , Xiao-Yu Hu . Supramolecular prodrug vesicles for selective antimicrobial therapy employing a chemo-photodynamic strategy. Chinese Chemical Letters, 2025, 36(3): 109999-. doi: 10.1016/j.cclet.2024.109999
4. [4]
  Xiaofang Luo , Ye Wu , Xiaokun Zhang , Min Tang , Feiye Ju , Zuodong Qin , Gregory J Duns , Wei-Dong Zhang , Jiang-Jiang Qin , Xin Luan . Peptide-based strategies for overcoming multidrug-resistance in cancer therapy. Chinese Chemical Letters, 2025, 36(1): 109724-. doi: 10.1016/j.cclet.2024.109724
5. [5]
  Jiechen Liu , Xiaoguang Li , Ruiyang Xia , Yuqi Wang , Fenghe Zhang , Yongzhi Pang , Qing Li . Efficient suppression of oral squamous cell carcinoma through spatial dimension conversion drug delivery systems-enabled immunomodulatory-photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109619-. doi: 10.1016/j.cclet.2024.109619
6. [6]
  Di ZHANG , Tianxiang XIE , Xu HE , Wanyu WEI , Qi FAN , Jie QIAO , Gang JIN , Ningbo LI . Construction and antitumor activity of pH/GSH dual-responsive magnetic nanodrug. Chinese Journal of Inorganic Chemistry, 2025, 41(4): 786-796. doi: 10.11862/CJIC.20240329
7. [7]
  Shuheng Zhang , Yuanyuan Zhang , Wanyu Wang , Yuzhu Hu , Xinchuan Chen , Bilan Wang , Xiang Gao . A combination strategy of DOX and VEGFR-2 targeted inhibitor based on nanomicelle for enhancing lymphoma therapy. Chinese Chemical Letters, 2024, 35(12): 109658-. doi: 10.1016/j.cclet.2024.109658
8. [8]
  Zhaomin Tang , Qian He , Jianren Zhou , Shuang Yan , Li Jiang , Yudong Wang , Chenxing Yao , Huangzhao Wei , Keda Yang , Jiajia Wang . Active-transporting of charge-reversal Cu(Ⅱ)-doped mesoporous silica nanoagents for antitumor chemo/chemodynamic therapy. Chinese Chemical Letters, 2024, 35(7): 109742-. doi: 10.1016/j.cclet.2024.109742
9. [9]
  Jing Zhang , Charles Wang , Yaoyao Zhang , Haining Xia , Yujuan Wang , Kun Ma , Junfeng Wang . Application of magnetotactic bacteria as engineering microrobots: Higher delivery efficiency of antitumor medicine. Chinese Chemical Letters, 2024, 35(10): 109420-. doi: 10.1016/j.cclet.2023.109420
10. [10]
  Yong-Dan Zhao , Yidan Wang , Rongrong Wang , Lina Chen , Hengtong Zuo , Xi Wang , Jihong Qiang , Geng Wang , Qingxia Li , Canqi Ping , Shuqiu Zhang , Hao Wang . Reversing artemisinin resistance by leveraging thermo-responsive nanoplatform to downregulating GSH. Chinese Chemical Letters, 2024, 35(6): 108929-. doi: 10.1016/j.cclet.2023.108929
11. [11]
  Yixuan Wang , Jiexin Li , Zhihao Shang , Chengcheng Feng , Jianmin Gu , Maosheng Ye , Ran Zhao , Danna Liu , Jingxin Meng , Shutao Wang . Wettability-driven synergistic resistance of scale and oil on robust superamphiphobic coating. Chinese Chemical Letters, 2024, 35(7): 109623-. doi: 10.1016/j.cclet.2024.109623
12. [12]
  Yuxin Li , Chengbin Liu , Qiuju Li , Shun Mao . Fluorescence analysis of antibiotics and antibiotic-resistance genes in the environment: A mini review. Chinese Chemical Letters, 2024, 35(10): 109541-. doi: 10.1016/j.cclet.2024.109541
13. [13]
  Shaoqing Du , Xinyong Liu , Xueping Hu , Peng Zhan . Targeting novel sites represents an effective strategy for combating drug resistance. Chinese Chemical Letters, 2025, 36(1): 110378-. doi: 10.1016/j.cclet.2024.110378
14. [14]
  Zengchao Guo , Weiwei Liu , Tengfei Liu , Jinpeng Wang , Hui Jiang , Xiaohui Liu , Yossi Weizmann , Xuemei Wang . Engineered exosome hybrid copper nanoscale antibiotics facilitate simultaneous self-assembly imaging and elimination of intracellular multidrug-resistant superbugs. Chinese Chemical Letters, 2024, 35(7): 109060-. doi: 10.1016/j.cclet.2023.109060
15. [15]
  Jin Wang , Xiaoyan Pan , Junyu Zhang , Qingqing Zhang , Yanchen Li , Weiwei Guo , Jie Zhang . Active molecule-based theranostic agents for tumor vasculature normalization and antitumor efficacy. Chinese Chemical Letters, 2024, 35(8): 109187-. doi: 10.1016/j.cclet.2023.109187
16. [16]
  Liping Zhao , Xixi Guo , Zhimeng Zhang , Xi Lu , Qingxuan Zeng , Tianyun Fan , Xintong Zhang , Fenbei Chen , Mengyi Xu , Min Yuan , Zhenjun Li , Jiandong Jiang , Jing Pang , Xuefu You , Yanxiang Wang , Danqing Song . Novel berberine derivatives as adjuvants in the battle against Acinetobacter baumannii: A promising strategy for combating multi-drug resistance. Chinese Chemical Letters, 2024, 35(10): 109506-. doi: 10.1016/j.cclet.2024.109506
17. [17]
  Hong-Tao Ji , Yu-Han Lu , Yan-Ting Liu , Yu-Lin Huang , Jiang-Feng Tian , Feng Liu , Yan-Yan Zeng , Hai-Yan Yang , Yong-Hong Zhang , Wei-Min He . Nd@C₃N₄-photoredox/chlorine dual catalyzed synthesis and evaluation of antitumor activities of 4-alkylated sulfonyl ketimines. Chinese Chemical Letters, 2025, 36(2): 110568-. doi: 10.1016/j.cclet.2024.110568
18. [18]
  Guangyao Wang , Zhitong Xu , Ye Qi , Yueguang Fang , Guiling Ning , Junwei Ye . Electrospun nanofibrous membranes with antimicrobial activity for air filtration. Chinese Chemical Letters, 2024, 35(10): 109503-. doi: 10.1016/j.cclet.2024.109503
19. [19]
  Han Han , Bi-Te Chen , Jia-Rong Ding , Jin-Ming Si , Tian-Jiao Zhou , Yi Wang , Lei Xing , Hu-Lin Jiang . A PDGFRβ-targeting nanodrill system for pancreatic fibrosis therapy. Chinese Chemical Letters, 2024, 35(10): 109583-. doi: 10.1016/j.cclet.2024.109583
20. [20]
  Jialiang XU , Jiabin CUI . Recent biological applications of corroles: From diagnosis to therapy. Chinese Journal of Inorganic Chemistry, 2024, 40(12): 2303-2317. doi: 10.11862/CJIC.20240245

Get Citation

PDF

XML

Metrics

PDF Downloads(3)
Abstract views(493)
HTML views(12)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142